Intensive Care Medicine

, Volume 33, Issue 7, pp 1162–1167 | Cite as

Safety and efficacy of colistin compared with imipenem in the treatmentof ventilator-associated pneumonia: a matched case–control study

  • H. Kallel
  • L. Hergafi
  • M. Bahloul
  • A. Hakim
  • H. Dammak
  • H. Chelly
  • C. Ben Hamida
  • A. Chaari
  • N. Rekik
  • M. Bouaziz



Our study aimed to determine the efficacy and safety of colistin in the treatment of ventilator-associated pneumonia (VAP) caused by pan-drug-resistant Pseudomonas aeruginosa or Acinetobacter baumanii.


Pairwise, retrospective exposed–unexposed study.


Combined medical and surgical intensive care unit of Habib Bourguiba University Hospital (Sfax, Tunisia).


Sixty patients with VAP caused by pan-drug-resistant A. baumanii or P. aeruginosa matched to 60 controls with VAP caused by A. baumanii or P. aeruginosa susceptible to imipenem. All patients had normal renal function at the onset of antibiotic therapy.


Case patients were treated by colistin intravenously and control patients were treated by imipenem intravenously.

Measurements and results

Baseline characteristics were similar between the colistin and imipenem groups. The mean duration of antibiotic therapy for VAP was 9.5 ± 3.8 days (range 5–22 days) with colistin and 8.9 ± 2.8 days (range 5–20 days) with imipenem (p = 0.32). A favorable clinical response to antibiotic therapy for VAP occurred in 45 patients (75%) in the colistin group and in 43 patients (71.7%) in the imipenem group (p = 0.68). The time to resolution of infectious parameters after the initiation of antibiotic therapy was not statistically different between the two groups. During the antibiotic course, none of the patients in either group developed renal failure.


We conclude that colistin can be a safe and effective option in the treatments of VAP caused by pan-drug-resistant P. aeruginosa or A. baumanii.


Colistin Ventilator-associated pneumonia Nephrotoxicity Imipenem 


  1. 1.
    Jones RN (2001) Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 119:397S–404SPubMedCrossRefGoogle Scholar
  2. 2.
    Flournoy DJ, Reinert RL, Bell-Dixon C, Gentry CA (2000) Increasing antimicrobial resistance in gram-negative bacilli isolated from patients in intensive care units. Am J Infect Control 28:244–250PubMedCrossRefGoogle Scholar
  3. 3.
    Reina R, Estenssoro E, Saenz G, Canales HS, Gonzalvo R, Vidal G, Martins G, Das Neves A, Santander O, Ramos C (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31:1058–1065PubMedCrossRefGoogle Scholar
  4. 4.
    Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10:R27PubMedCrossRefGoogle Scholar
  5. 5.
    Olesen S, Madsen PO (1967) Intravenous administration of sodium colistimethate in urinary tract infections. Curr Ther Res Clin Exp 9:283–287PubMedGoogle Scholar
  6. 6.
    Price DJ, Graham DI (1970) Effects of large doses of colistin sulphomethate sodium on renal function. Br Med J 4:525–527PubMedCrossRefGoogle Scholar
  7. 7.
    Tripathi VN, Stulberger EA, Takacs FJ (1970) Colistimethate overdosage. J Urol 104:176–178PubMedGoogle Scholar
  8. 8.
    Devlieger H, Casteels-Van Daele M, Ki MB, Proesmans W (1977) Acute renal failure due to colistin intoxication. Acta Paediatr Belg 30:179–181PubMedGoogle Scholar
  9. 9.
    Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF (1999) Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumanii. Clin Infect Dis 28:1008–1011PubMedGoogle Scholar
  10. 10.
    Jimenez-Mejias ME, Becerril B, Marquez-Rivas FJ, Pichardo C, Cuberos L, Pachon J (2000) Successful treatment of multidrug-resistant Acinetobacter baumanii meningitis with intravenous colistin sulfomethate sodium. Eur J Clin Microbiol Infect Dis 19:970–971PubMedCrossRefGoogle Scholar
  11. 11.
    Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Martin-Lozano D, Prados T, Pachon J (2002) Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumanii meningitis. Eur J Clin Microbiol Infect Dis 21:212–214PubMedCrossRefGoogle Scholar
  12. 12.
    Stein A, Raoult D (2002) Colistin: an antimicrobial for the 21st century? Clin Infect Dis 35:901–902PubMedCrossRefGoogle Scholar
  13. 13.
    Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L (2003) Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7:R78–83PubMedCrossRefGoogle Scholar
  14. 14.
    Ouderkirk JP, Nord JA, Turett GS, Kislak JW (2003) Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 47:2659–2662PubMedCrossRefGoogle Scholar
  15. 15.
    Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D (2003) Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 37:e154–160PubMedCrossRefGoogle Scholar
  16. 16.
    Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-WittelI M, Gallego-Lara SL, Madrazo-Osuna J (2003) Treatment of multidrug-resistant Acinetobacter baumanii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111–1118PubMedCrossRefGoogle Scholar
  17. 17.
    Karabinis A, Paramythiotou E, Mylona-Petropoulou D, Kalogeromitros A, Katsarelis N, Kontopidou F, Poularas I, Malamou-Lada H (2004) Colistin for Klebsiella pneumonia-associated sepsis. Clin Infect Dis 38:e7–9PubMedCrossRefGoogle Scholar
  18. 18.
    Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A (2005) Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 26:504–507PubMedCrossRefGoogle Scholar
  19. 19.
    Reina R, Estenssoro E, Saenz G, Canales HS, Gonzalvo R, Vidal G, Martins G, Das Neves A, Santander O, Ramos C (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31:1058–1065PubMedCrossRefGoogle Scholar
  20. 20.
    Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, Hamida CB, Rekik N, Hammami A, Bouaziz M (2006) Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents. 28:366–369PubMedCrossRefGoogle Scholar
  21. 21.
    Kallel H, Bahloul M, Ksibi H, Dammak H, Chelly H, Hamida CB, Chaari A, Rekik N, Bouaziz M (2005) Prevalence of hospital-acquired infection in a Tunisian hospital. J Hosp Infect 59:343–347PubMedCrossRefGoogle Scholar
  22. 22.
    Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963PubMedCrossRefGoogle Scholar
  23. 23.
    Marquette CH, Georges H, Wallet F, Ramon P, Saulnier F, Neviere R, Mathieu D, Rime A, Tonnel AB (1993) Diagnostic efficiency of endotracheal aspirates with quantitative bacterial cultures in intubated patients with suspected pneumonia. Comparison with the protected specimen brush. Am Rev Respir Dis 148:138–144PubMedGoogle Scholar
  24. 24.
    Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ (2001) Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 163:1371–1375PubMedGoogle Scholar
  25. 25.
    Anon (2000) Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standards document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA, USAGoogle Scholar
  26. 26.
    Anon (2000) Performance standard for antimicrobial susceptibility testing. Document M100-S10. National Committee for Clinical Laboratory Standards, Wayne, PA, USAGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • H. Kallel
    • 1
  • L. Hergafi
    • 1
  • M. Bahloul
    • 1
  • A. Hakim
    • 2
  • H. Dammak
    • 1
  • H. Chelly
    • 1
  • C. Ben Hamida
    • 1
  • A. Chaari
    • 1
  • N. Rekik
    • 1
  • M. Bouaziz
    • 1
  1. 1.Service de Réanimation MédicaleCHU Habib BourguibaSfaxTunisia
  2. 2.Laboratoire de PharmacologieFaculté de Médecine de SfaxSfaxTunisia

Personalised recommendations